Navigation Links
Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/31/2008

Year Ended December 31,

2007 2006

(Audited) (Audited)

Revenues $26,384,608 $15,932,075

Other Sales -- 2,937

Cost of goods sold (13,913,034) (9,594,852)

Gross profit 12,471,574 6,340,160

Selling expenses (1,581,655) (599,571)

General and administrative expenses

Amortization of intangible assets (141,681) (96,615)

Amortization of debt issue costs (201,255) --

Depreciation (333,964) (132,747)

Bad debts (287,482) (364,064)

Director remuneration (94,247) --

Penalty to investors (1,022,275) --

Finder fee (293,751) --

Cash bonus -- --

Consulting and professional fees (8,353,615) (326,403)

Other general and administrative

expenses (3,173,307) (1,533,775)

Total general and administrative

expenses (13,901,577) (2,453,604)

Gains / (losses) on disposals of fixed

assets (30,027) (249,381)

Research and development expenses (553,962) (30,821)

Total operating expenses (16,067,221) (3,333,377)

Operating income / (loss) (3,595,647) 3,006,783

Interest income / (expense) (3,389,676) (108,811)

Other income (expenses) 55,964 (281,190)

Government subsidies / grants 2,276,574 --

Income /
'/>"/>

SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Pharmaceutical Strategic Initiatives Adds Anne Sexton, MD, MS to Management Team
2. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
3. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
4. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
5. Barr Pharmaceuticals, Inc. Executive Bios
6. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
7. Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A Clean Slate Approach to the Practice of Pharmaceutical Care
8. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
9. Surveys Find Key Changes in the Role of the Pharmaceutical CFO
10. KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K
11. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...g their appointments with their doctors and practi...ted by Developing //Patient Partnerships. The poll...he doctors were not kept while 5 million practice ...ast year. The problem is more prevalent in London ...
...sue of the Journal, Vascular Surgery, researchers ...ve found //that certain risks factors put people y...l vascular disease (PVD). The findings were based...ple younger than 60 and a similar number of people...
...dical Center scientists have discovered that alter...d clues to the reasons why// certain people are vu...TA2 and the army of genes it manipulates may actua...rtery disease. This finding may also show the way ...
...erved that public health and prevention often get ...funding. This is probably// because the significan... saved through expensive, high-tech medical care i...urces could help several more people through preve...
Other Medicine News:Health News:Gene variants hold clues about vulnerability to cardiovascular disease 2Health News:Gene variants hold clues about vulnerability to cardiovascular disease 3Health News:Gene variants hold clues about vulnerability to cardiovascular disease 4Health News:Lives Saved through Simple Changes 2
(Date:10/8/2008)...s Research That May Offer New Hope to,Heart Failur...nally, over 3,000 people are,waiting for a heart t...alf,of those will receive a transplant. Now, pione... paving the way for how to treat congestive heart,...ews Release, go to:, http://www.prnewswire.com/mnr...
(Date:10/8/2008)...e TAXUS(R) Element(TM) Platinum Chromium ... 8 /- Boston Scientific,Cor... completed enrollment in,the PERSEUS trial, design...S(R) Element(TM) paclitaxel-eluting coronary stent... 1,500 patients at 100 U.S. and,international cent...
(Date:10/8/2008)...ical improvement in patients with pulmonary a...t options have limited benefit for this debilitati...essel disease, -- Imatinib mesylate, available ...s, known to inhibit protein associated with PAH, ...inib mesylate in PAH in 2009 EAST HANOVER, N...
(Date:10/7/2008)... device for detecting polyps that can be ...Fla., Oct. 7 /- At the American Colle...n Orlando (ACG 2008), renowned,gastroenterologist ...institutional clinical study that evaluated the ef...vice that is designed to improve the ability,of ph...
Breaking Medicine Technology:Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Handbook helps parents deal with childhood infections 1024 1Handbook helps parents deal with childhood infections 1024 2Speed plays crucial role in breaking proteins H bonds 1022 1Speed plays crucial role in breaking proteins H bonds 1022 2Speed plays crucial role in breaking proteins H bonds 1022 3Fuel cells gearing up to power auto industry 1020 1Fuel cells gearing up to power auto industry 1020 2Fuel cells gearing up to power auto industry 1020 3Michigan Cosmetic Surgeon Debunks Top 3 Breast Implant Myths 4974 1Michigan Cosmetic Surgeon Debunks Top 3 Breast Implant Myths 4974 2
...eady being treated with maximally,tolerated lipid-...ons in LDL-C with similar reductions in other athe... NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007...nc. announced,results from its ongoing Phase 2 cli...gous familial hypercholesterolemia (HoFH),present...
... 2007 /PRNewswire-FirstCall/ --,Alfacell Corporati...nstrating the potential of ONCONASE (ranpirnase) f...CLC) were recently,published in Anticancer Researc...ae Lee, Ph.D., at the University of,Pennsylvania, ...xic,RNase, Ranpirnase, on A549 Human Lung Cancer X...
Other Medicine Technology:Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 3Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 4Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 6In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research 2In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research 3
Last 3-6 months average refrigeration will prolong life. Pupil gauge printed on penlight 4 1/2" long 1/2" around.
Maxi-Lite diagnostic penlight features a twist-on backswitch.
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra
Heavy duty, all purpose illuminator available in black only. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentrated l
Medicine Products: